ALLO News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

AL

Mkt Cap

$450.9M

Volume

4.16M

Next Earnings

November 5th

Loading chart

AL

ALLOAllogene Therapeutics, Inc. Common Stock

ALLO

Pay with—

Available Balance0.00

AL

Mkt Cap

$452.6M

Volume

4.16M

Next Earnings

November 5th

Chart Financials Earnings News About Insider Filings

Allogene Therapeutics Announces Pricing of Public Offering of Common StockAllogene Therapeutics priced an underwritten public offering of 87.5 million shares at $2.00 per share, raising $175 million in gross proceeds. The company plans to use net proceeds for clinical trials, R&D, and general corporate purposes. The offering is expected to close on April 16, 2026, with Goldman Sachs, Jefferies, and TD Cowen serving as joint bookrunners.GlobeNewswire Inc. · Apr 15, 2026

Allogene Arbitration Victory Pressures Cellectis Shares TuesdayAllogene Therapeutics won an arbitration against Cellectis regarding CAR-T therapy development rights, securing full control of cemacabtagene ansegedleucel in the U.S., EU, and U.K., while the tribunal rejected Cellectis's financial claims and allegations.Benzinga · Dec 16, 2025

Allogene Therapeutics Reports Favorable Result for Servier in Arbitration with CellectisAllogene Therapeutics won a favorable arbitration ruling with Cellectis, reconfirming full development and commercial control of cemacabtagene ansegedleucel (cema-cel) in the US, EU, and UK, with a path to acquire full global rights by 2026.GlobeNewswire Inc. · Dec 15, 2025

U.S. CAR T-Cell Therapies Market Grows at 30.4% CAGR, Soars USD 42.61 Billion by 2035The U.S. CAR T-cell therapies market is expected to grow from USD 3.43 billion in 2026 to USD 42.61 billion by 2035, driven by rising cancer cases, research investments, and innovative therapeutic approaches.GlobeNewswire Inc. · Nov 27, 2025

High‑Growth Oncology Market Projected For US$900bn in Revenue Despite Policy HeadwindsDespite regulatory challenges and budget cuts, the oncology market is projected to reach US$900 billion by 2034, with several biotech companies advancing innovative cancer therapies and demonstrating promising clinical trial results.Benzinga · Jul 23, 2025

Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCOAllogene Therapeutics presented updated data from the Phase 1 TRAVERSE study of ALLO-316 in renal cell carcinoma, showing promising results with a 31% confirmed response rate and durable responses in heavily pretreated patients.GlobeNewswire Inc. · Jun 1, 2025

CAR T-cell Therapy Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 180+ Companies Working in the DomainThe CAR T-cell therapy pipeline is experiencing significant momentum, with over 180 companies actively developing more than 200 pipeline therapies. The report highlights promising pipeline candidates and recent advancements in the field, indicating the growing potential of this revolutionary cancer treatment approach.GlobeNewswire Inc. · Mar 5, 2025

Oncology in Focus: How Emerging Therapies Are Reshaping Cancer TreatmentThe oncology field is advancing with emerging immunotherapies and AI-driven personalized cell therapies. Key players like Oncolytics Biotech, Erasca, Allogene Therapeutics, Context Therapeutics, and Recursion Pharmaceuticals are driving progress in areas like breast, GI, and renal cell cancers.Benzinga · Dec 26, 2024

Gene Therapy Clinical Trial Pipeline Gains Momentum: 180+ Companies Lead the Charge in Pioneering New Treatments | DelveInsightThe gene therapy market is experiencing significant growth, with over 180 companies actively developing more than 200 gene therapies. This dynamic landscape highlights the increasing investment and innovation in the sector, promising new treatment options for various diseases.GlobeNewswire Inc. · Oct 22, 2024

Gene Editing Therapeutics Market Forecast 2024-2029: A $1 Billion Market by 2029, with a Forecasted CAGR of 147%The gene editing therapeutics market is expected to grow significantly, reaching $1 billion by 2029 with a CAGR of 147%. Key drivers include the increasing prevalence of chronic and rare genetic diseases, as well as the need for precision medicine.GlobeNewswire Inc. · Sep 10, 2024

to start trading

AL

ALLOAllogene Therapeutics, Inc. Common Stock

ALLO

Pay with—

Available Balance0.00

Your PositionYou don't own any ALLO yet.

Related Tickers

Earnings